hrp0092p1-192 | Fat, Metabolism and Obesity (1) | ESPE2019

Changes in Objectively Measured Sleep Quality After an Integral Intervention in Patients with Abdominal Obesity

Azcona Cristina , Catalán Ana , Morell Lydia , Ojeda Ana , Chueca María , Marti Amelia

Aim: to study sleep quality, using accelerometry in children and adolescents with abdominal obesity after a multidisciplinary intervention.Patients, Material and Methods: we included 122 children and adolescents, range age: 7 to 16 years old, diagnosed with abdominal obesity (waist circumference > p90) who participated in an 8-week intervention program to lose weight, with a 2-year follow-up period. Participants were...

hrp0086p2-p512 | Fat Metabolism and Obesity P2 | ESPE2016

Weight Status in Children at 8 Years: A Prospective Cohort Study

Riano-Galan Isolina , Cristina Rodriguez-Dehli Ana , Olaya-Vazquez Ines , Fernandez-Somoano Ana , Tardon Adonina

Background: Prevalence of childhood obesity represents a major public health concern, given the tracking of body weight from childhood to adult age and its health sequelae.Objective: To describe prevalence of overweight (OW) and obesity (OB) in children at 8 years and investigate the relationship with pre-pregnancy maternal weight and weight status at 4 years.Methods: 485 pregnant mothers recruited between 2004 and 2007 and 409 chi...

hrp0082p2-d3-404 | Fat Metabolism & Obesity (2) | ESPE2014

Cystic Fibrosis: Dyslipidemia in Brazilian Children

Araujo Ana Catarina , Bezerra Ana Cristina , Monte Luciana , Moreira Cristina , Abdalla Andrea

Background: Cystic fibrosis is associated with abnormal lipid metabolism and this anormality is commonly characterized by low cholesterol and hypertriglyceridemia. The increasing in life expectancy of cystic fibrosis patients has enhancing the interest for prevent the risk factors for cardiovascular diseases like dyslipidemias.Objective and hypotheses: Determine whether concentrations of cholesterol and triacylglycerol are related to nutritional status a...

hrp0097p1-563 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Clinical and analytical presentation of central precocious puberty according to age: a 20-year retrospective study

Luísa de Carvalho Ana , Matilde Carvalho Rita , Martins Sofia , Antunes Ana , Miguel Gomes Maria

Introduction: Central Precocious Puberty (CPP) results from the premature activation of the hypothalamic-pituitary-gonadal axis. Is defined by the onset of secondary sexual characters before 8-years-old in girls and 9-years-old in boys. It’s associated with accelerated growth and advanced bone maturation and can lead to early epiphyseal fusion and reduced final height at adult age.Aims: To evaluate and compare the ...

hrp0097p2-75 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Foetal exposures to endocrine-disrupting chemicals. INMA-ASTURIAS COHORT. SPAIN.

Cristina Rodríguez-Dehli Ana , Fernández-Somoano Ana , Riaño Galán Isolina , Tardon Adonina

Background: Endocrine-disrupting chemicals (EDCs) are serious and urgent threats to public health, due to the potentially serious adverse effects of EDCs on endocrine processes during susceptible periods of human development.Objective: To evaluate the levels endocrine disruptors at gestation.Material and methods: A pilot study. Data were obtained from 30 pregnant mothers recruited ...

hrp0097p2-95 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Short-term impact of therapy with GNRH analogues on the growth of female children with central precocious puberty: a retrospective study of the last 20 years

Luísa de Carvalho Ana , Carvalho Adriana , Martins Sofia , Antunes Ana , Miguel Gomes Maria

Introduction: Since the 1980s, long-acting gonadotropin-releasing hormone analogues (GnRHa) have been the standard treatment for central precocious puberty (CPP).Aims: To evaluate the short-term response (at 6 and 12 months) of treatment with GnRHa in female children diagnosed with CPP, regarding growth, bone maturation (Greulich and Pyle method), predicted adult height (PAH) and pubertal development (Tanner stages)....

hrp0082p2-d1-450 | Growth | ESPE2014

Identification of NPR2 Mutations in Disproportionate Short Stature

Hisado-Oliva Alfonso , Benito-Sanz Sara , Belinchon Alberta , Vallespin Elena , del Pozo Angela , Barreda-Bonis Ana C. , Ramirez Joaquin , Luzuriaga Cristina , Gonzalez-Casado Isabel , Campos-Barros Angel , Heath Karen E.

Background: Homozygous natriuretic peptide receptor-2 (NPR2) mutations cause acromesomelic dysplasia, type Maroteaux, a skeletal dysplasia with extreme disproportionate short stature and recently, heterozygous NPR2 mutations have been identified also in patients with idiopathic short stature (ISS, 2–6%). SHOX mutations are found in ~2–5% of ISS cases and ~70% of Léri-Weill dyschondrosteosis (LWD) cases, characterized by disproportionat...

hrp0082fc11.2 | Pituitary | ESPE2014

Novel SOX2 Mutation: Identification of New Molecular Mechanisms of SOX2 Action and Interactions

Alatzoglou Kyriaki S. , Andoniadou Cynthia L. , Kelberman Daniel , Kim Hyoong-Goo , Botse-Baidoo Edward , Pedersen-White Jennifer , Layman Lawrence , Martinez-Barbera Juan Pedro , Dattani Mehul T.

Background: SOX2 is an early developmental transcription factor implicated in pituitary development; heterozygous SOX2 mutations have been reported in patients with a severe ocular phenotype and hypogonadotrophic hypogonadism (HH) with/without associated abnormalities. SOX2 physically interacts with β-catenin, a member of the Wnt-signalling pathway, via its carboxyl-terminus and it represses in vitroβ-catenin mediated activation.<p class="abstex...

hrp0094fc9.5 | Growth Hormone and IGFs | ESPE2021

Dynamic Changes in Growth and IGF-I During the First Year of Life; A Longitudinal Study of 233 healthy Danish Infants

Upners Emmie N. , Ljubicic Marie L , Busch Alexander S , Fischer Margit B , Almstrup Kristian , Petersen Jorgen H , Jensen Rikke B , Hagen Casper P , Juul Anders ,

Background: Growth during infancy is a continuation of the rapid fetal growth and its regulation is complex and multifactorial. It is well-established that insulin-like growth factor-I (IGF-I) and its regulators (e.g. IGF binding proteins (IGFBP-3) and pregnancy-associated plasma protein-A2 (PAPP-A2)) are important for prenatal and postnatal growth; however, their significance for growth during infancy is not fully explored.Aims: The aim...

hrp0092p1-72 | GH and IGFs | ESPE2019

Diagnostic Value of Random Serum Growth Hormone (GH), IGF-I and IGFBP-3 Concentrations for the Diagnosis of Growth Hormone Deficiency (GHD) in Patients Below One Year of Life

Ballerini María Gabriela , Braslavsky Débora , Freire Analía Verónica , Keselman Ana , Rodríguez María Eugenia , Altube Mercedes , Scaglia Paula Alejandra , Bergadá Ignacio , Ropelato María Gabriela

GHD diagnosis in neonates and infants is a challenge owing to the fact that GH pharmacological stimulation tests (GHST) are not approved at this age. In a retrospective study, we found that a random GH<6.5 µg/L confirmed GHD diagnosis in neonates with clinical suspicion of GHD with high diagnostic accuracy (1). The accuracy of GH and its surrogates of action have not been set for infants with current standardized immunoassays.Objective</...